A study to assess long-term health and socioeconomic outcomes in neonatal-onset multisystem inflammatory disease patients on treatment with IL-1 blockade (anakinra or canakinumab)
Latest Information Update: 14 Jan 2021
At a glance
- Drugs Anakinra (Primary) ; Canakinumab (Primary)
- Indications Cryopyrin-associated periodic syndromes
- Focus Therapeutic Use
- 14 Jan 2021 New trial record